Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Notes Payables (2019 - 2025)

Burning Rock Biotech has reported Notes Payables over the past 7 years, most recently at $83467.6 for Q4 2025.

  • For Q4 2025, Notes Payables rose 1.28% year-over-year to $83467.6; the TTM value through Dec 2025 reached $83467.6, up 1.28%, while the annual FY2025 figure was $85000.0, 4.94% up from the prior year.
  • Notes Payables for Q4 2025 was $83467.6 at Burning Rock Biotech, up from $28000.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $370690.7 in Q4 2021 and troughed at $28000.0 in Q3 2025.
  • A 5-year average of $155516.6 and a median of $161500.0 in 2021 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: tumbled 93.16% in 2021 and later soared 187.72% in 2023.
  • Year by year, Notes Payables stood at $370690.7 in 2021, then crashed by 31.61% to $253509.2 in 2022, then plummeted by 34.42% to $166248.2 in 2023, then plummeted by 50.43% to $82415.7 in 2024, then increased by 1.28% to $83467.6 in 2025.
  • Business Quant data shows Notes Payables for BNR at $83467.6 in Q4 2025, $28000.0 in Q3 2025, and $83000.0 in Q2 2025.